NEC OncoImmunity AS
@OncoImmunity
Followers
221
Following
61
Media
2
Statuses
65
NEC OncoImmunity AS develops bioinformatics software to empower precision cancer immunotherapy, using machine-learning to profile neoantigens from NGS data.
Oslo, Norway
Joined January 2016
Learn more about our collaboration with Nagasaki university in the infectious disease space #ai #drugdiscovery #biopharma #vaccines #globalhealth
https://t.co/LskxYCG29B
nec.com
Nagasaki University and NEC OncoImmunity (NOI), a leading artificial intelligence (AI) company, have announced that they will collaborate to use NOI’s AI platform to design universal vaccines against...
0
0
0
NEC Oncoimmunity bags $4.8M to develop vaccines for SARS-CoV-2 variants, other betacoronaviruses https://t.co/vBk7jOzbnD
#biotech #biopharma #biotechnology #BiotechNews #LifeSciencesNews #biopharmaceutical #lifesciences #pharma @CEPIvaccines @OncoImmunity
0
3
1
CEPI støtter norske NEC @OncoImmunity som bruker kunstig intelligens i utviklingen av en bredspektret betakoronavaksine @DagensMedisin 🇳🇴
dagensmedisin.no
Med kunstig intelligens skal norske NEC OncoImmunity finne vaksine-antigener som kan gi bred beskyttelse mot ulike varianter av betakoronavirus. Prosjektet får inntil 42 millioner kroner i CEPI-stø...
0
6
7
A major milestone for our team! Congrats to all involved https://t.co/WdzPynuTLP
nec.com
CEPI, the Coalition for Epidemic Preparedness Innovations, and NEC Corporation (NEC: TSE: 6701) today announced the latest funding award under its US$200m programme to advance the development of...
0
1
6
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets: Press Releases | NEC
nec.com
NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate...
0
2
7
We are hiring! Looking for talented people to use their data science and software skills in the fight against cancer and infectious diseases. https://t.co/SQupknT0Tf
finn.no
NEC OncoImmunity is a machine-learning based company providing software to empower personalized cancer immunotherapy, and infectious disease.
0
2
2
Exciting to see our AI approach to develop universal blueprints for vaccine design now published in the peer review journal Scientific Reports
0
1
2
An artificial intelligence T-cell diagnostic test for COVID-19
businesswire.com
NEC OncoImmunity AS (NOI), a subsidiary of NEC Corporation (NEC), and Oslo University Hospital (OUH) are pleased to announce that they have recently been awa...
0
2
3
NEC’s AI-driven Blueprint for a Safe, Universally Effective New Coronavirus Vaccine: Business Insights | NEC
nec.com
NEC’s AI-driven Blueprint for a Safe, Universally Effective New Coronavirus Vaccine
0
1
4
@OncoImmunity is recruiting a Quality Assurance Manager - Join our team and help build quality #ai software to combat cancer and infectious disease:
finn.no
Job description:NEC OncoImmunity is looking for a Quality Assurance (QA) Manager to join our team and contribute to the development of innovative software
0
0
2
@OncoImmunity is recruiting a Quality Assurance Manager - Join our team and help build quality #ai software to combat cancer and infectious disease:
0
2
2
Congratulations to the team for their hard work in adapting the NEC Immune Profiler technology to help in the fight against COVID-19 #AI #COVID19vaccine
https://t.co/NMMzFBUEUd
financialpost.com
0
2
4
Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2: toward universal blueprints for vaccine designs
biorxiv.org
The global population is at present suffering from a pandemic of Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The...
0
3
9
It's been a pleasure to work with Richard, @Trevor_Clancy, @andtuv and the rest of the team, and we're very proud to have been part of this journey! Further, we are excited about the opportunities that lie ahead, and look forward to seeing what OncoImmunity going forward!
0
2
9
Huge congrats to our portfolio company @OncoImmunity - now acquired by @NEC_corp. A great merger that increases OncoImmunity’s reach, ensuring that their machine learning software improves cancer treatments for as many people as possible! https://t.co/FO8uHhWGVG
nec.com
NEC Corporation (NEC; TSE: 6701) today announced the acquisition of OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight...
6
10
30
scRNA-seq reveals heterogeneity in the CD56bright NK cell subset and nondramatic transitioning into CD56dim NK cells @Trevor_Clancy @AlinePfefferle and Herman Netskar https://t.co/o7n0BvPj6S
2
11
30
OncoImmunity was pleased to present exciting results on improved neoantigen presentation and immunogenicity at the #NeoAg Summit today
linkedin.com
OncoImmunity was pleased to present exciting results on improved neoantigen presentation and immunogenicity at the #NeoAg Summit today
1
3
12
Gode nyheter rett før påskeferien: @IselinNybo @Kunnskapsdep har gitt beskjed til EU om at Norge vil delta i #HorisontEuropa 👏 Med økt budsjett og større fokus på skalering av bedrifter lover dette godt for norsk næringsliv! #EIC @InnovasjonNorge
0
4
14
"We believe that OncoImmunity's Immuneoprofiler™ software represents the best-in-class solution for predicting clinically relevant bona fide neoantigens." said Reid Rubsamen, CEO of Flow Pharma. Congratulations to the dedicated OncoImmunity team!
Looking forward to start an exciting neoantigen project with Flow Pharma and their powerful vaccine technology #neoantigen #personalizedmedicine
https://t.co/hA3hXJd2T1 …
0
2
10